Ascentage Pharma announced that olverembatinib has been included in the latest guidelines from the National Comprehensive Cancer Network for the management of Chronic Myeloid Leukemia,[1] marking a major development in global recognition for its best-in-class drug candidate, which has been approved in China for the management of tyrosine kinase inhibitor -resistant patients with chronic- and accelerated-phase CML.
